A phase 3 Prospective, Randomized, Double-Masked, 12-week, parallel group Study evaluating the efficacy and safety of Latanoprost and Timolol in Pediatric subjects with Glaucoma [more info]

A randomized, double-masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trop-Eye in subjects with neovascular age-related [more info]

A phase 1, Open-Label study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated with Latanoprost 0,005% [more info]

An Exploratory, Multicenter, Patient-masked, Dose-escalation, Paired-eye Comparison, Sham-controlled, 6-Month (Plus 6-Month Extension) Study to Evaluate the Safety and Effects on Visual Function of 100ug, 200 ug, and 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Patients with Retinitis Pigmentosa [more info]

A Multicenter, Investigator-Masked, Parallel-Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0,1% Eyedrops Compared with Kerorolac 0,5% Eyedrops in Ocular Inflammation After Cataract Surgery [more info]

A 6-Month, Single-Masked, Multicenter, Randomized, Controlled Study to Assess the Safety and Efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® Compared with Lucentis® Alone in the Treatment of Patients with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration [more info]

Long term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered at the therapeutic recommended doses (2.5/5/7.5 mg b.i.d.) on top of anti anginal background therapy, to patients with chronic stable angina pectoris. An international, double-blind placebo controlled study [more info]

A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) [more info]

Early Markers of choroidal neovascularization (CNV) in fellow eyes of patients with Age-Related Macular Degeneration (AMD) and CNV in one eye [more info]

A phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® compared with Lucentis® monotherapy every 4 weeks in patients with Exsudative Age-Related Macular Degeneration (AMD) [more info]

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.003mg Pagaptanib Sodium (Macugen®), Given as Often as Every 6 Weeks for 3 years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) involving the Center of the Macula [more info]

A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema [more info]

Study of the Efficacy and Safety of Travatan® Therapy compared with Cosopt® Therapy in Patients with Open-Angle Glaucoma or Ocular Hypertension [more info]

A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and afety of 0.5mg and 1.25mg fingolimod (FTY720) administered orally once daily versus interferon ?-1a (Avonex®) administered i.m. Once weekly in patients with relapsing-remitting multiple sclerosis [more info]

An 8-week, multicenter, masked, randomized trial (with an 18-week masked extension) to assess the safety and efficacy of 700 ug and 350 ug dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system compared with sham DEX PS DDS applicator system in the treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate uveitis [more info]

A randomized, double-masked, parallel group, multi-center, dose-finding comparison of the safety and efficacy of ASI-001A 0.5 ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema [more info]

A 102-week, open label, multicenter trial to investigate the efficacy of macugen for the preservation of visual function in subjects with neovascular age-related macular degeneration (AMD) and to assess the benefit of treating early choroidal neovascularization (CNV) [more info]

An extension of the double-blind, randomized, placebo-controlled, parrallel-group, multicenter study evaluating safety, tolerability and effet on MRI lesion parameters of FTY720 vs placebo in patients with relapsing multiple sclerosis [more info]

The effect of Ruboxistaurin on Clinically significant macular edema in patients with diabetes Mellitus, as assessed by optical coherence tomography [more info]

A Six- Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the safety and Efficacy of 700ug and 350ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion [more info]

Protocol B7A-MC-MBDL. Reduction in the Occurence of center-threatening diabetic macular edema [more info]

A five-year, multicenter, open-label study to evaluate the safety of once-daily evening instillation of travoprost 0,004% eyedrops (Travatran®) in subjects with open-angle glaucoma or ocular hypertension. [more info]

Areas of expertise

• Characterisation and evaluation of the most recent methods to study the initial stages of diabetic retinopathy
• Evaluation of new methodologies for multimodal mapping of the macula
• Studies of the diseases of the choroid and retina and especially of their blood circulation
• Testing new methods of early diagnosis and characterisation of macular edema and retinal vascular pathology
• Evaluation of new drugs to treat glaucoma. Development of methods to correlate clinical indicators of disease progression, particularly regarding optic nerve degeneration and the mechanisms of the actions of drugs being tested
• Evaluation of the quality of cataract microsurgery, testing new drugs for surgery procedures